From: Efficacy and safety of caspofungin for patients with hepatic insufficiency
Group | Time | Albumin g/L | ALT U/L | AST U/L | ALP U/L | GGT U/L | TBIL U/L | Scr mmol/L | eGFR mL/min |
---|---|---|---|---|---|---|---|---|---|
A | D0 D1 D7 D14 X2 P | 31.8 (29–35) 32.4 (29–34) 30.1 (26–33) 31.6 (29–37) 6.39 0.09 | 17.5 (8–35) 16.0 (9–31) 25.5 (14–48) 19.5 (12–36) 3.38 0.29 | 19.5 (16–28) 16.5 (13–26) 20.0 (15–26) 22.0 (12–35) 4.91 0.18 | 89.0 (59–113) 86.0 (74–118) 94.7 (81–103) 96.0 (64–128) 1.41 0.70 | 38.0 (19–92) 42.0 (27–84) 38.5 (26–61) 36.0 (22–82) 2.08 0.56 | 8.6 (6–15) 8.8 (5.5–14) 10.7 (6–15) 11.1 (9–19) 2.35 0.50 | 56.4 (47–131) 57.4 (45–108) 69.0 (44–115) 65.5 (42–126) 0.60 0.89 | 86.8 (38–130) 88.6 (38–139) 88.4 (41–131) 85.9 (31–145) 0.96 0.81 |
B | D0 D1 D7 D14 X2 P | 28.1 (26–31) 27.6 (25–29) 29.5 (27–31) 30.1 (27–34)# 13.03 0.005 | 26.0 (14–68) 27.0 (12–50) 28.0 (10–41) 20.5 (11–37) 9.24 0.03 | 42.5 (23–56) 44.5 (24–59) 38.0 (25–61) 32.0 (20–52) 9.92 0.03 | 110.0 (71–174) 116.0 (72–175) 115.5 (74–182) 134.0 (69–186) 1.14 0.77 | 79.5 (46–129) 82.5 (49–134) 79.0 (49–123) 63.5 (41–86) 5.04 0.17 | 20.5 (10–52) 17.4 (13–67) 25.1 (10–55) 18.6 (9–48) 4.99 0.17 | 77.7 (48–112) 65.7 (48–98) 49.5 (37–80)*# 58.3 (39–80)*# 28.05 0.00 | 85.1 (42–105) 81.4 (48–100) 103.9 (65–134) *# 105.4 (59–138) *# 22.6 0.00 |
C | D0 D1 D7 D14 X2 P | 29.1 (26–32) 30.1 (27–33) 30.7 (28–33) 31.8 (27–34) 2.29 0.51 | 49.5 (35–91) 50.0 (26–110) 45.0 (22–73) 37.0 (21–73) 9.65 0.02 | 76.0 (56–123) 73.0 (53–113) 81.5 (49–117) 71.0 (42–98) 2.18 0.54 | 135.0 (100–164) 132.0 (110–171) 117.0 (73–150) 115.0 (93–150) 6.08 0.11 | 51.0 (30–81) 51.0 (28–91) 56.0 (34–80) 46.0 (30–74) 0.19 0.76 | 240.9 (110–371) 263.1 (88–388) 227.3 (109–335) 196.0 (64–332) 3.61 0.31 | 71.3 (52–101) 65.5 (43–80) 61.4 (41–77) 68.9 (54–91) 1.33 0.72 | 102.9 (59–136) 106.9 (71–144) 110.5 (59–139) 104.8 (60–130) 0.88 0.83 |